Circulating Biomarkers Market Revenue to Attain USD 12.71 Bn by 2033

Published: 14 Nov 2025

Author: Precedence Research

Share :

Table of Content

1. Circulating Biomarkers Market Revenue and Trends 2025 to 2033 2. What are the key factors boosting the growth of the circulating biomarkers market? 3. Segment Insights: 4. Regional Insights: 5. Circulating Biomarkers Market Coverage

Circulating Biomarkers Market Revenue and Trends 2025 to 2033

The global circulating biomarkers market revenue reached USD 5.17 billion in 2025 and is predicted to attain around USD 12.71 billion by 2033 with a CAGR of 11.90%. Advances in minimally invasive assays and liquid biopsy platforms are expanding the use of circulating biomarkers for early disease detection, treatment monitoring, and personalized care, thus fueling market growth.

What are the key factors boosting the growth of the circulating biomarkers market?

The growing prevalence of cancers, cardiovascular diseases, and other chronic conditions underscores the urgent need for timely diagnostic tools capable of detecting diseases at an earlier, more treatable stage. Simultaneously, technological advancements, including next-generation sequencing, enhanced bioinformatics, and multiplex biomarker assays, are improving the sensitivity and specificity of tests using circulating biomarkers.

The adoption of blood- or fluid-based sampling, rather than invasive tissue biopsies, has also increased the practicality of these tests in clinical settings. Years of increased funding from central governments, diagnostic companies, and research institutions have led to a faster pace of biomarker discovery, validation, and commercialization. The collaboration between diagnostics providers and biotechnology firms has expanded the portfolio of circulating biomarker assays. These combined forces have created a robust and expanding market for circulating biomarkers.

Segment Insights:

• By type, the circulating DNA segment dominated the market in 2024, as it offers robust, non-invasive detection and monitoring capabilities and remains the most widely adopted circulating biomarker type.
• By application, the hospital segment dominated the market in 2024, as hospitals are at the forefront of adopting circulating biomarker tests for diagnostic screening, patient monitoring, and integration into clinical workflows.

Regional Insights:

North America dominated the circulating biomarkers market in 2024, driven by its advanced healthcare infrastructure, substantial research and development investments, and the strong presence of leading global diagnostic companies. Furthermore, North America's early adoption and subsequent expansion in liquid biopsy and personalized medicine have significantly boosted market growth. Supportive government policies, high public awareness of non-invasive diagnostics, and a well-established reimbursement framework further solidify North America's position as a key leader for the development and commercialization of circulating biomarkers.

Asia Pacific is expected to grow at the fastest rate in the coming years, driven by increased healthcare spending, rapid technological advancements in diagnostics, and the rising prevalence of chronic diseases. The expanding number of diagnostic laboratories, government-funded research initiatives, and partnerships between regional and global biotech firms are all contributing to heightened demand. Furthermore, the increasing emphasis on early disease diagnosis and the progress of personalized medicine in rapidly developing countries like China, India, and South Korea are significantly transforming the circulating biomarkers landscape.

Circulating Biomarkers Market Coverage

Recent Developments:

• On October 20, 2025, ClearNote Health announced presentations at the ESMO Congress 2025 showcasing its Avantect pancreatic and multi-cancer tests, built on its Virtuoso platform, which quantifies cell-free DNA (cfDNA) and epigenomic biomarkers for early cancer detection in high-risk patient populations. (Source- https://www.biospace.com)
• In April 2025, the "Circulating Biomarkers Europe 2025" conference was added to ResearchAndMarkets.com's offering. It focused on key classes of circulating biomarkers, including extracellular vesicles (EVs), circulating cell-free DNA (cfDNA), circulating tumor cells (CTCs), and circulating RNAs and oncoproteins. The event provided a scientific deep dive into technologies, tools, and biological studies advancing understanding of these biomarkers and their roles in various biological processes.

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7055

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344